Phaseline

Companies › Matrix Biomed

Matrix Biomed: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Cardiovascular, Gastroenterology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tempol
Free radical scavenger and antioxidant
–Phase 2Mucositis; Healthy–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03480971TempolPhase 2MucositisGastroenterologyJul 2025
NCT06424756TempolPhase 2HealthyCardiovascularMar 2030

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Livzon Pharmaceutical Group Noorik Biopharmaceuticals Tectonic Operating Company CuraSen Therapeutics Neurimmune

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.